2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesHumansHypoglycemic AgentsInformation DisseminationRandomized Controlled Trials as TopicRisk FactorsRosiglitazoneConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2011
Birthweight and mortality in adulthood: a systematic review and meta-analysis
Risnes KR, Vatten LJ, Baker JL, Jameson K, Sovio U, Kajantie E, Osler M, Morley R, Jokela M, Painter RC, Sundh V, Jacobsen GW, Eriksson JG, Sørensen TI, Bracken MB. Birthweight and mortality in adulthood: a systematic review and meta-analysis. International Journal Of Epidemiology 2011, 40: 647-661. PMID: 21324938, DOI: 10.1093/ije/dyq267.Peer-Reviewed Original ResearchConceptsHazard ratioCardiovascular diseaseBirth sizeCardiovascular mortalityHigher birthweightInverse associationObservational studyLong-term mortalityGeneric inverse varianceRisk of obesityStrong inverse associationSmall birth sizeLarge birth sizeLong-term healthCause mortalityCancer mortalityCancer deathEpidemiology guidelinesResidual confoundingLower riskBirthweightMeta-AnalysisSystematic reviewMortalityInverse variance